In vitro synergistic effect of retapamulin with erythromycin and quinupristin against Enterococcus faecalis.
Anti-Bacterial Agents
/ therapeutic use
Bridged Bicyclo Compounds, Heterocyclic
/ therapeutic use
Diterpenes
/ therapeutic use
Drug Synergism
Enterococcus faecalis
/ drug effects
Enterococcus faecium
/ drug effects
Erythromycin
/ therapeutic use
Gram-Positive Bacterial Infections
/ drug therapy
Humans
Macrolides
/ therapeutic use
Microbial Sensitivity Tests
Staphylococcus aureus
/ drug effects
Streptococcus pyogenes
/ drug effects
Virginiamycin
/ analogs & derivatives
Journal
The Journal of antibiotics
ISSN: 1881-1469
Titre abrégé: J Antibiot (Tokyo)
Pays: England
ID NLM: 0151115
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
14
02
2020
accepted:
07
04
2020
revised:
28
03
2020
pubmed:
30
4
2020
medline:
29
12
2020
entrez:
30
4
2020
Statut:
ppublish
Résumé
To find a therapeutic alternative for the treatment of skin and soft tissue infections, we evaluated the effects of combinations of retapamulin with macrolide, lincosamide, and streptogramin (MLS) antibiotics against Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecium, and Enterococcus faecalis. Using both the disk diffusion test and checkerboard assay, we initially examined the effects of combinations of retapamulin with MLS antibiotics against standard strains of these species. Combinations of retapamulin with erythromycin, quinupristin/dalfopristin and quinupristin showed synergistic activity against E. faecalis only. Synergy of retapamulin with clindamycin and dalfopristin was not observed. Then, a checkerboard assay was performed to evaluate the effects of the combinations against 15 clinical strains of E. faecalis. Retapamulin and quinupristin, the most synergistic combination, showed activity against all erythromycin-susceptible, -intermediate, and -resistant strains tested. Among the eight strains with high-level erythromycin resistance, five strains were synergistically inhibited in the presence of only 1 μg of retapamulin per ml. Time-kill assay revealed that combinations of retapamulin with erythromycin and quinupristin were bacteriostatic. These results suggest that combinations of retapamulin with erythromycin and quinupristin have in vitro synergistic activity against E. faecalis, including strains with high-level erythromycin resistance.
Identifiants
pubmed: 32346089
doi: 10.1038/s41429-020-0312-7
pii: 10.1038/s41429-020-0312-7
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bridged Bicyclo Compounds, Heterocyclic
0
Diterpenes
0
Macrolides
0
Virginiamycin
11006-76-1
quinupristin-dalfopristin
126602-89-9
quinupristin
23OW28RS7P
retapamulin
4MG6O8991R
Erythromycin
63937KV33D
dalfopristin
R9M4FJE48E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
630-635Références
Higuita NIA, Huycke MM. Enterococcal disease, epidemiology, and implications for treatment. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: from commensals to leading causes of drug resistant infection. Boston: Massachusetts Eye and Ear Infirmary; 2014.
Kristich CJ, Rice LB, Arias CA. Enterococcal infection–treatment and antibiotic resistance. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: from commensals to leading causes of drug resistant infection. Boston: Massachusetts Eye and Ear Infirmary; 2014.
Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanism in enterococcus. Virulence. 2012;3:421–569.
doi: 10.4161/viru.21282
Conly JM, Johnston BL. Mupirocin—are we in danger of losing it?. Can J Infect Dis 2002;13:157–9.
doi: 10.1155/2002/692581
Sood S, Malhotra M, Das BK, Kapil A. Enterococcal infections and antimicrobial resistance. Indian J Med Res. 2008;128:111–21.
pubmed: 19001673
Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. Drug Resist Update. 2018;40:25–39.
doi: 10.1016/j.drup.2018.10.002
Bai B, Hu K, Zeng J, Yao W, Li D, Pu Z, et al. Linezolid consumption facilitates the development of linezolid resistance in Enterococcus faecalis in a tertiary-care hospital: a 5-year surveillance study. Microb Drug Resist. 2019;25:791–8.
doi: 10.1089/mdr.2018.0005
Schwarz S, Shen J, Kadlec K, Wang Y, Michael GB, Feßler AT, et al. Lincosamides, streptogramins, phenicols, and pleuromutilins: mode of action and mechanisms of resistance. Cold Spring Harb Perspect Med. 2016;6:a027037.
doi: 10.1101/cshperspect.a027037
Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol. 2005;3:870–81.
doi: 10.1038/nrmicro1265
Pillai SK, Moellering RCJ, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, editor. Antibiotics in laboratory medicine. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2005.
Odds FC. Synergy, antagonism, and what the checkerboard puts between them. J Antimicrob Chemother. 2003;52:1.
doi: 10.1093/jac/dkg301
Traczewski MM, Brown SD. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob Agents Chemother. 2008;52:3863–7.
doi: 10.1128/AAC.00399-08